GlassScriptPhysician profile
Ethan S Van Til
NPI 1255323309
$1,848.95
in general payments reported to CMS, 2019-2025
31 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $121 · 2021: $26.44 · 2022: $208 · 2023: $297 · 2024: $361 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450.41 | 2022-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $204.64 | 2019-2025 | |
| Amgen INC. | $135.47 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $133.42 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Dexcom, INC. | $107.68 | 2022-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $70.21 | 2024-2025 | Breztri |
| Janssen Pharmaceuticals, INC | $68.03 | 2020-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $65.73 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $58.59 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $55.66 | 2019-2024 | Jardiance |
| Inspire Medical Systems, INC. | $47.42 | 2024 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $47.29 | 2019-2025 | Eliquis |
| Astellas Pharma US INC | $41.94 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $40.15 | 2019 | |
| Sumitomo Pharma America, INC. | $25.63 | 2025 | Gemtesa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $24.89 | 2019 | |
| Boston Scientific Corporation | $24.48 | 2023 | |
| Daiichi Sankyo INC. | $24.27 | 2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $21.76 | 2020 | |
| Axsome Therapeutics, INC. | $20.49 | 2025 | Auvelity |
| Radius Health, INC. | $20.41 | 2023 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $20.18 | 2025 | |
| Medtronic, INC. | $19.50 | 2022 | |
| Seqirus USA INC | $19.38 | 2025 | Fluad, Flucelvax |
| Organon LLC | $17.04 | 2025 | Nuvaring, Nexplanon |
| Esperion Therapeutics, INC. | $16.79 | 2025 | Nexletol |
| Exact Sciences Corporation | $16.14 | 2025 | Cologuard Collection Kit |
| Insulet Corporation | $14.11 | 2019 | |
| Amarin Pharma, INC. | $12.98 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.25 | 2019 | |
| Mylan Specialty L.P. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Van Til listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.